NASD · Healthcare · Biotechnology · Canada
Lexaria Bioscience Corp is a micro cap company (market value under $300 million) in the Biotechnology industry.
Lexaria Bioscience Corp develops DehydraTECH, a patented delivery technology that enhances how active pharmaceutical ingredients enter the bloodstream. The technology combines APIs with long-chain fatty acid-rich triglyceride oils and works with molecules including GLP-1 and GIP drugs, vitamins, antivirals, and cannabinoids. DehydraTECH can be incorporated into tablets, capsules, beverages, and foods for pharmaceutical and consumer applications, with the company licensing its technology to industry participants.
From its FY2025 annual report (Form 10-K)
Intrinsic value, DCF valuation, financial health and value investing analysis for the Lexaria Bioscience Corp stock.
Overvalued: intrinsic value $0.90 per share, market price $3.49, margin of safety -287.7% (as of 2026-10-30).
Its liquidation floor, current assets minus every liability, values the shares at $0.90; the price of $3.49 is 288% above that value.
79 more in this industry show a wider margin of safety.
LEXX is overvalued (as of the 2026-10-30 close). Its liquidation floor, current assets minus every liability, values the shares at $0.90; the price of $3.49 is 288% above that value.
$0.90 per share (as of the 2026-10-30 close), against a market price of $3.49. That is a margin of safety of -287.7%. The value is the average of the valuation methods that apply to this company, recomputed every night after the US close.